First Generic of HIV-1 Antiretroviral Atazanavir Launches in the U.S.

Brand-name Reyataz (Bristol-Myers Squibb) generated annual sales of more than $400 million in 2017

Teva Pharmaceutical Industries Ltd. has launched the first generic version of Reyataz (atazanavir, Bristol-Myers Squibb) capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection for patients 6 years of age and older weighing at least 15 kg.

Reyataz® had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.

Source: Teva; December 27, 2017.